Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study

Thomas Urup; W Z Pawlak; P M Petersen; H Pappot; M Rørth; G Daugaard

doi:10.1038/bjc.2013.229

Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study

Thomas Urup, W Z Pawlak, P M Petersen, H Pappot, M Rørth, G Daugaard

28 Citations (Scopus)

Abstract

Adrenocortical carcinoma (ACC) is a rare disease with a poor response to chemotherapy. Cisplatin is the most widely investigated drug in the treatment of ACC and in vitro studies have indicated activity of taxanes. The objectives of this study were to evaluate the efficacy and toxicity of cisplatin combined with docetaxel as first-line treatment of advanced ACC.

Original language	English
Journal	B J C
Volume	108
Issue number	10
Pages (from-to)	1994-7
Number of pages	4
ISSN	0007-0920
DOIs	https://doi.org/10.1038/bjc.2013.229
Publication status	Published - 28 May 2013

Keywords

Adrenal Cortex Neoplasms
Adrenocortical Carcinoma
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Cisplatin
Disease Progression
Female
Humans
Male
Middle Aged
Survival Analysis
Taxoids
Treatment Outcome
Young Adult

Access to Document

10.1038/bjc.2013.229

Cite this

@article{29dd804bb7df471ea626066eaf3d2c2e,

title = "Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study",

abstract = "Adrenocortical carcinoma (ACC) is a rare disease with a poor response to chemotherapy. Cisplatin is the most widely investigated drug in the treatment of ACC and in vitro studies have indicated activity of taxanes. The objectives of this study were to evaluate the efficacy and toxicity of cisplatin combined with docetaxel as first-line treatment of advanced ACC.",

keywords = "Adrenal Cortex Neoplasms, Adrenocortical Carcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Disease Progression, Female, Humans, Male, Middle Aged, Survival Analysis, Taxoids, Treatment Outcome, Young Adult",

author = "Thomas Urup and Pawlak, \{W Z\} and Petersen, \{P M\} and H Pappot and M R{\o}rth and G Daugaard",

year = "2013",

month = may,

day = "28",

doi = "10.1038/bjc.2013.229",

language = "English",

volume = "108",

pages = "1994--7",

journal = "B J C",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study

AU - Urup, Thomas

AU - Pawlak, W Z

AU - Petersen, P M

AU - Pappot, H

AU - Rørth, M

AU - Daugaard, G

PY - 2013/5/28

Y1 - 2013/5/28

N2 - Adrenocortical carcinoma (ACC) is a rare disease with a poor response to chemotherapy. Cisplatin is the most widely investigated drug in the treatment of ACC and in vitro studies have indicated activity of taxanes. The objectives of this study were to evaluate the efficacy and toxicity of cisplatin combined with docetaxel as first-line treatment of advanced ACC.

AB - Adrenocortical carcinoma (ACC) is a rare disease with a poor response to chemotherapy. Cisplatin is the most widely investigated drug in the treatment of ACC and in vitro studies have indicated activity of taxanes. The objectives of this study were to evaluate the efficacy and toxicity of cisplatin combined with docetaxel as first-line treatment of advanced ACC.

KW - Adrenal Cortex Neoplasms

KW - Adrenocortical Carcinoma

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Cisplatin

KW - Disease Progression

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Survival Analysis

KW - Taxoids

KW - Treatment Outcome

KW - Young Adult

UR - https://www.scopus.com/pages/publications/84878580813

U2 - 10.1038/bjc.2013.229

DO - 10.1038/bjc.2013.229

M3 - Journal article

C2 - 23652308

SN - 0007-0920

VL - 108

SP - 1994

EP - 1997

JO - B J C

JF - B J C

IS - 10

ER -

Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this